Bayer Bets $1.3B On Kumquat Cancer Drug Candidate
By Jade Martinez-Pogue · August 12, 2025, 6:16 PM EDT
Pharmaceutical company Bayer and Kumquat Biosciences Inc., a clinical-stage biotech company, on Tuesday announced that they have entered into an exclusive global license and collaboration agreement under which Kumquat will receive...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login